HALO News and Press, Halozyme Therapeutics Inc. From 04/04/21

As the patron saint of value investors, Warren Buffett's strategies for picking stocks -- and his preferences for holding them for the long term -- are so well-known that they're practically cliches. But don't let your familiarity with his approach trick you into thinking that it's stale. B...

I tested James O'Shaughnessy's two most favored investment strategies from the fourth edition of What Works on Wall Street over the post-publication (2010-2021) period. I hazard some reasons why one of them failed during that period and suggest some improvements. I conclude with s...

Looking For The Best Health Care Stocks To Watch Right Now? 4 Names To Know You can’t deny that health care is a vital industry in the world we live in today. Similarly, health care stocks have and will likely continue to fill the same role in the stock market. With all e...

Halozyme Therapeutics (HALO) has priced $700M of its 0.25% convertible senior unsecured notes due 2027 in a private placement.Initial purchasers to purchase up to an additional $105M of Convertible Notes. Interest will be payable semi-annually in arrearsOffering is expected to close on March ...

Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $700 Million of Convertible Senior Notes due 2027 PR Newswire SAN DIEGO , Feb. 24, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company"), a leader in...

Halozyme Therapeutics (NASDAQ: HALO) was well in double-digit territory on Wednesday, as its stock was up by over 14% in mid-afternoon trading. That action followed the company's release of its latest set of quarterly results after market close the preceding day. For its fourth ...

Image source: The Motley Fool. Halozyme Therapeutics Inc (NASDAQ: HALO) Q4 2020 Earnings Call Feb 23, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Halozyme Therapeutics Inc (HALO) Q4 2020 Earnings Call Transcript...

Halozyme Therapeutics, Inc. (HALO) Q4 2020 Earnings Conference Call February 23, 2021 04:30 PM ET Company Participants Al Kildani - Vice President of Investor Relations & Corporate Communications Helen Torley - President & Chief Executive Officer Elaine Sun - Chief Financial Officer C...

The following slide deck was published by Halozyme Therapeutics, Inc. in conjunction with their 2020 Q4 earnings call. For further details see: Halozyme Therapeutics, Inc. 2020 Q4 - Results - Earnings Call Presentation

Halozyme Therapeutics (HALO) announces that it intends to offer $500M aggregate principal amount of convertible senior notes due 2027.The company also expects to grant a 30-day option to the initial purchasers to purchase up to an additional $75M aggregate principal amount of convertible note...